Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007962 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
A Phase 3 study of Immune Thrombocytopenia, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 10
- Study locations
NCT07007962 is a Phase 3 study of Immune Thrombocytopenia that is actively recruiting participants, run by Sanofi. The registered enrollment target is 60 participants, below the 114-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (47% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT07007962, a Phase 3 study of Immune Thrombocytopenia, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.
Conditions Studied
Interventions
- DRUG rilzabrutinib
Study Locations (10)
Other
- Investigational Site Number: 2500003 - Créteil
- Investigational Site Number : 2500001 - Dijon
- Investigational Site Number : 2500002 - Pessac
- Investigational Site Number : 2500004 - Toulouse
- Investigational Site Number : 3480002 - Kaposvár
- Investigational Site Number : 6160003 - Skorzewo
- Investigational Site Number : 6160004 - Słupsk
Minnesota
- Mayo Clinic_Investigational Site Number: 8400009 - Rochester
New York
- New York Oncology Hematology_Investigational Site Number: 8400010 - Albany
Utah
- Community Cancer Trials of Utah_Investigational Site Number: 8400002 - Ogden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007962
The ClinicalTrials.gov registry entry for NCT07007962 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (47% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which rilzabrutinib is the first listed.
NCT07007962 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT07007962 about?
NCT07007962 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment". This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-ter...
What is the current status of trial NCT07007962?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-10-24. Estimated completion is 2028-12-30.
What conditions does trial NCT07007962 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia.
What interventions are being tested in trial NCT07007962?
The interventions under investigation include: rilzabrutinib (DRUG).
Who is sponsoring clinical trial NCT07007962?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007962 being conducted?
This trial has 10 study locations across Minnesota, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
COMPLETED · Phase 3
-
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
RECRUITING · Phase 2
-
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
RECRUITING
-
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.